數字療法/健康:主要趨勢、商業模式、市場預測(2022-2026 年)
市場調查報告書
商品編碼
1066075

數字療法/健康:主要趨勢、商業模式、市場預測(2022-2026 年)

Digital Therapeutics & Wellness: Key Trends, Business Models & Market Forecasts 2022-2026

出版日期: | 出版商: Juniper Research Ltd | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

本報告分析了全球數字治療和數字健康市場,戰略性地分析了市場的基本結構/趨勢、機會/問題、主要市場促進/制約因素以及主要公司概況。我們將為您提供諸如作為競爭形勢,整體市場規模趨勢展望(未來 5 年的用戶數、收入等),按細分市場劃分的詳細趨勢等。

目錄

市場趨勢與策略

第1章重點和戰略建議

第2章調查大綱

  • 簡介
  • 定義
    • 數字治療(數字治療)
    • 數字健康
  • 調查範圍

第3章市場動態

  • 數字治療
    • 醫療服務和改進的互操作性
    • 科學驗證和監管批准
      • 美國因 COVID-19 放鬆管制
    • 人工智能和機器學習
      • 聊天機器人的複雜性和“恐怖谷”
    • 慢性病患病率增加
  • 數字健康
    • 企業健康
    • 更廣泛的市場吸引力和利益
    • 銷售渠道和多元化
    • 用戶隱私和可靠性

第4章價值鏈與商業模式

  • 數字治療
    • 價值鏈
      • 數字療法供應商
      • 系統集成商
      • 保險當局
      • 臨床醫生和雇主
      • 醫療保險公司
      • 最終用戶
    • 商業模式
      • 數字療法供應商
      • 系統集成商
      • 醫療保險公司
  • 數字健康
    • 價值鏈
      • 數字健康供應商
      • 雇主
      • 醫療保險公司
      • 消費者
    • 商業模式
      • 數字健康供應商
      • 醫療保險公司

競技排行榜

第 1 章瞻博網絡研究排行榜

第 2 章供應商簡介

  • 2明天
    • 公司簡介
    • 各地區的擴張狀況
    • 與主要客戶的戰略合作夥伴關係
    • 產品和服務概覽
    • Juniper Research 的觀點:主要優勢和戰略機遇
  • Big Health
  • Click Therapeutics
  • Happify Health
  • Headspace Health
  • Kaia Health
  • Livongo
  • my mhealth
  • Omada Health
  • Pear Therapeutics
  • Sidekick Health
  • Vida Health
  • Voluntis
  • Wise Therapeutics
  • Welldoc

數據與預測:目錄

第 1 章調查概述

第 2 章市場概述:數字治療/健康

  • 市場概況
    • 數字療法/健康產品的用戶數量
    • 數字治療/健康總收入

第 3 章市場概述:數字治療

  • 簡介
  • 假設是一種研究方法
  • 市場概況
    • Digital Therapeutics 用戶數量
    • 數字療法總收入
  • 細分市場預測
    • 哮喘/慢性阻塞性肺病
    • 心血管疾病(CVD)/高血壓
    • 糖尿病
    • 物理治療
    • 禁止吸煙
    • 體重管理

第 4 章市場概述:數字健康

  • 簡介
  • 假設是一種研究方法
    • 消費者健康
      • 數字健康應用用戶數
      • 正在使用的數字健康應用數量
      • 通過訂閱計劃獲利的數字健康應用數量
      • 消費者數字健康總收入
    • 企業健康
      • 參加企業健康計劃的員工人數
      • 企業的健康總收入
  • 市場概況
    • 數字健康產品的用戶數量
    • 數字健康總收入
  • 細分市場預測
    • 消費者健康
    • 企業健康
簡介目錄

Juniper Research's “Digital Therapeutics & Wellness ” research includes a complete evaluation of the key drivers, trends, and challenges facing the digital therapeutics and wellness market. These are allied to a set of comprehensive 5-year forecasts and an in-depth assessment of the disruptive potential and market strategies of the leading digital therapeutics players.

The research suite includes:

  • 1. Market Trends & Strategies: Strategic analysis of key market dynamics and opportunities, together with a detailed analysis of the digital therapeutics and wellness value chain (PDF).
  • 2. Market Data & Forecasting: In-depth forecasts for market size and growth, including number of people using digital therapeutics, number of consumer wellness apps in use, number of employees enrolled in corporate wellness schemes, and total revenue (PDF).
  • 3. Competitor Leaderboard: Leading digital therapeutics vendors assessed and scored in our Competitor Leaderboard, underpinned by interviews with players and robust scoring methodologies (PDF).
  • 4. Interactive Forecast Excel: Highly granular dataset comprising more than 96,000 datapoints; allied to an Interactive Scenario tool; giving users the ability to manipulate Juniper Research's data (Interactive XL).
  • 5. harvest Online Data Platform: 12 months' access to the report's data in our online data platform, including continuous data updates and exportable charts, tables and graphs (Online).

Table of Contents

Market Trends & Strategies

1. Key Takeaways & Strategic Recommendations

  • 1.1 Digital Therapeutics
    • 1.1.1 Key Takeaways
    • 1.1.2 Strategic Recommendations
  • 1.2 Digital Wellness
    • 1.2.1 Key Takeaways
    • 1.2.2 Strategic Recommendations

2. Research Introduction

  • 2.1 Introduction
  • 2.2 Definitions
    • 2.2.1 Digital Therapeutics
    • 2.2.2 Digital Wellness
      • Figure 2.1: Segment Overlap of Digital Wellness and Digital Therapeutics
  • 2.3 Research Scope

3. Market Dynamics

  • 3.1 Digital Therapeutics
    • 3.1.1 Improved Healthcare Delivery & Interoperability
      • Figure 3.1: Number of People Using Digital Therapeutics (m), Split by 8 Key Regions, 2022-2026
    • 3.1.2 Scientific Validation & Regulatory Approval
      • i. Deregulation in the US Due to COVID-19
    • 3.1.3 Artificial Intelligence & Machine Learning
      • i. Chatbot Complexity & the Uncanny Valley
    • 3.1.4 Growing Prevalence of Chronic Conditions
      • Figure 3.2: Number of People Using Digital Therapeutics (m), Split by Addressed Condition, 2026
  • 3.2 Digital Wellness
    • 3.2.1 Corporate Wellness
    • 3.2.2 Wider Market Appeal & Benefits
      • Figure 3.3: Total Revenue from Corporate Wellness Programmes ($m), Split by Key 8 Regions, 2022-2026
    • 3.2.3 Sales Channels & Diversification
    • 3.2.4 User Privacy & Trust

4. Value Chain & Business Models

  • 4.1 Digital Therapeutics
    • 4.1.1 Value Chain
      • i. Digital Therapeutics Vendors
      • ii. Systems Integrators
      • iii. Health Regulators
      • iv. Clinicians and Employers
      • v. Health Insurers
      • vi. End Users
        • Figure 4.1: Digital Therapeutics Value Chain
    • 4.1.2 Business Models
      • i. Digital Therapeutics Vendors
        • Figure 4.2: Total Digital Therapeutics Revenue ($m), Split by Payer, 2026
      • ii. Systems Integrators
      • iii. Health Insurers
  • 4.2 Digital Wellness
    • 4.2.1 Value Chain
      • i. Digital Wellness Vendors
      • ii. Employers
      • iii. Health Insurers
      • iv. Consumers
        • Figure 4.3: Digital Wellness Value Chain
    • 4.2.2 Business Models
      • i. Digital Wellness Vendors
      • ii. Health Insurers

Competitor Leaderboard

1. Juniper Research Leaderboard

  • 1.1 Why Read This Report
    • Table 1.1: Juniper Research Leaderboard: Featured Vendors & Conditions Addressed by Product Portfolio
    • Figure 1.2: Juniper Research Leaderboard: Digital Therapeutics Vendors
    • Table 1.3: Juniper Research Leaderboard: Digital Therapeutics Vendor Positioning
    • Table 1.4: Juniper Research Leaderboard Heatmap: Digital Therapeutics Vendors
  • 1.2 Leaderboard Assessment Methodology
    • 1.2.1 Limitations & Interpretations

2. Vendor Profiles

  • 2.1 2Morrow
    • i. Corporate
    • ii. Geographic Spread
    • iii. Key Clients & Strategic Partnerships
      • Figure 2.1: Advertisement for 2Morrow's Smoking Cessation Programme
    • iv. High-level View of Offerings
    • v. Juniper Research's View: Key Strengths & Strategic Opportunities
  • 2.2 Big Health
    • i. Corporate
      • Table 2.2: Investor Funding Received by Big Health, 2014-2022
    • ii. Geographic Spread
    • iii. Key Clients & Strategic Partnerships
    • iv. High-level View of Offerings
      • Figure 2.3: Sleepio UI
    • v. Juniper Research's View: Key Strengths & Strategic Opportunities
  • 2.3 Click Therapeutics
    • i. Corporate
    • ii. Geographic Spread
    • iii. Key Clients & Strategic Partnerships
      • Table 2.4: Investor Funding Received by Click Therapeutics, 2012-2021
    • iv. High-level View of Offerings
      • Table 2.5: Current Status of Click Therapeutics' Product Pipeline
    • v. Juniper Research's View: Key Strengths & Strategic Opportunities
  • 2.4 Happify Health
    • i. Corporate
    • ii. Geographic Spread
    • iii. Key Clients & Strategic Partnerships
    • iv. High-level View of Offerings
      • Figure 2.6: Ensemble UI
    • v. Juniper Research's View: Key Strengths & Strategic Opportunities
  • 2.5 Headspace Health
    • i. Corporate
    • ii. Geographic Spread
    • iii. Key Clients & Strategic Partnerships
    • iv. High-level View of Offerings
      • Figure 2.7: Headspace UI
    • v. Juniper Research's View: Key Strengths & Strategic Opportunities
  • 2.6 Kaia Health
    • i. Corporate
      • Table 2.8: Investor Funding Received by Kaia Health, 2016-2021
    • ii. Geographic Spread
    • iii. Key Clients & Strategic Partnerships
    • iv. High-level View of Offerings
      • Figure 2.9: Kaia MSK Therapy UI
    • v. Juniper Research's View: Key Strengths & Strategic Opportunities
  • 2.7 Livongo
    • i. Corporate
      • Table 2.10: Teladoc Health Financial Snapshot ($m), FY 2019-2021 (FYE 31 December)
    • ii. Geographic Spread
    • iii. Key Clients & Strategic Partnerships
    • iv. High-level View of Offerings
    • v. Juniper Research's View: Key Strengths & Strategic Opportunities
      • Figure 2.11: Livongo's AI+AI System
  • 2.8 my mhealth
    • i. Corporate
    • ii. Geographic Spread
    • iii. Key Clients & Strategic Partnerships
    • iv. High-level View of Offerings
      • Figure 2.12: myCOPD UI
    • v. Juniper Research's View: Key Strengths & Strategic Opportunities
  • 2.9 Omada Health
    • i. Corporate
    • ii. Geographic Spread
      • Table 2.13: Investor Funding Received by Omada Health, 2011-2020
    • iii. Key Clients & Strategic Partnerships
    • iv. High-level View of Offerings
      • Figure 2.14: Omada Insights Lab
    • v. Juniper Research's View: Key Strengths & Strategic Opportunities
  • 2.10 Pear Therapeutics
    • i. Corporate
    • ii. Geographic Spread
    • iii. Key Clients & Strategic Partnerships
    • iv. High-level View of Offerings
      • Table 2.15: Current Status of Pear Therapeutics' Product Pipeline
    • v. Juniper Research's View: Key Strengths & Strategic Opportunities
      • Figure 2.16: reSET UI
  • 2.11 Sidekick Health
    • i. Corporate
    • ii. Geographic Spread
    • iii. Key Clients & Strategic Partnerships
    • iv. High-level View of Offerings
    • v. Juniper Research's View: Key Strengths & Strategic Opportunities
  • 2.12 Vida Health
    • i. Corporate
    • ii. Geographic Spread
      • Table 2.17: Investor Funding Received by Vida Health, 2014-2021
    • iii. Key Clients & Strategic Partnerships
    • iv. High-level View of Offerings
      • Figure 2.18: Vida Health UI
    • v. Juniper Research's View: Key Strengths & Strategic Opportunities
  • 2.13 Voluntis
    • i. Corporate
      • Table 2.19: Voluntis Financial Snapshot ($m), FY 2018-2020 (FYE 31 December)
    • ii. Geographic Spread
    • iii. Key Clients & Strategic Partnerships
    • iv. High-level View of Offerings
      • Figure 2.20: Oleena UI
    • v. Juniper Research's View: Key Strengths & Strategic Opportunities
  • 2.14 Wise Therapeutics
    • i. Corporate
    • ii. Geographic Spread
    • iii. Key Clients & Strategic Partnerships
    • iv. High-level View of Offerings
      • Figure 2.21: Personal Zen UI
      • Table 2.22: Wise Therapeutics' Current Product Pipeline
    • v. Juniper Research's View: Key Strengths & Strategic Opportunities
  • 2.15 Welldoc
    • i. Corporate
    • ii. Geographic Spread
    • iii. Key Clients & Strategic Partnerships
    • iv. High-level View of Offerings
    • v. Juniper Research's View: Key Strengths & Strategic Opportunities
      • Figure 2.23: Bluestar for Diabetes UI

Data & Forecasting Table of Contents

1. Research Introduction

  • 1.1 Introduction
  • 1.2 Definitions
    • 1.2.1 Digital Therapeutics
    • 1.2.2 Digital Wellness
      • Figure 1.1: Segment Overlap of Digital Wellness and Digital Therapeutics
  • 1.3 Research Scope

2. Market Summary: Digital Therapeutics & Wellness

  • 2.1 Market Summary
    • 2.1.1 Number of People Using Digital Therapeutics & Wellness Products
      • Figure & Table 2.1: Number of People Using Digital Therapeutics & Wellness Products (m), Split by 8 Key Regions, 2021-2026
      • Table 2.2: Number of People Using Digital Therapeutics & Wellness Products (m), Split by Market, 2021-2026
      • Table 2.3: Number of People Using Digital Therapeutics & Wellness Products (m), Split by Business Model, 2021-2026
    • 2.1.2 Total Digital Therapeutics & Wellness Revenue
      • Figure 2.4: Total Digital Therapeutics & Wellness Revenue ($m), Split by 8 Key Regions, 2021-2026
      • Table 2.5: Total Digital Therapeutics & Wellness Revenue ($m), Split by Market, 2021-2026
      • Table 2.6: Total Digital Therapeutics & Wellness Revenue ($m), Split by Business Model, 2021-2026

3. Market Overview: Digital Therapeutics

  • 3.1 Introduction
  • 3.2 Methodology & Assumptions
    • 3.2.1 Number of People Using Digital Therapeutics
    • 3.2.2 Total Digital Therapeutics Revenue
      • Figure 3.1: Digital Therapeutics Forecast Methodology
  • 3.3 Market Summary
    • 3.3.1 Number of People Using Digital Therapeutics
      • Figure & Table 3.2: Number of People Using Digital Therapeutics (m), Split by 8 Key Regions, 2021-2026
    • 3.3.2 Total Digital Therapeutics Revenue
      • Figure & Table 3.3: Total Digital Therapeutics Revenue ($m), Split by 8 Key Regions, 2021-2026
      • Table 3.4: Total Digital Therapeutics Revenue ($m), Split by Payer, 2021-2026
  • 3.4 Segment Market Forecasts
    • 3.4.1 Asthma & COPD
      • i. Number of People Using Digital Therapeutics to Manage Asthma & COPD
        • Figure & Table 3.5: Number of People Using Digital Therapeutics to Manage Asthma & COPD (000's), Split by 8 Key Regions, 2021-2026
        • Table 3.6: Number of People Using Digital Therapeutics to Manage Asthma & COPD (000's), Split by Payer, 2021-2026
      • ii. Total Asthma & COPD Digital Therapeutics Revenue
        • Figure & Table 3.7: Total Asthma & COPD Digital Therapeutics Revenue ($m), Split by 8 Key Regions, 2021-2026
        • Table 3.8: Total Asthma & COPD Digital Therapeutics Revenue ($m), Split by Payer, 2021-2026
    • 3.4.2 CVD & Hypertension
      • i. Number of People Using Digital Therapeutics to Manage CVD & Hypertension
        • Figure & Table 3.9: Number of People Using Digital Therapeutics to Manage CVD & Hypertension (000's), Split by 8 Key Regions, 2021-2026
        • Table 3.10: Number of People Using Digital Therapeutics to Manage CVD & Hypertension (000's), Split by Payer, 2021-2026
      • ii. Total CVD & Hypertension Digital Therapeutics Revenue
        • Figure & Table 3.11: Total CVD & Hypertension Digital Therapeutics Revenue ($m), Split by 8 Key Regions, 2021-2026
        • Table 3.12: Total CVD & Hypertension Digital Therapeutics Revenue ($m), Split by Payer, 2021-2026
    • 3.4.3 Diabetes
      • i. Number of People Using Digital Therapeutics to Manage Diabetes
        • Figure & Table 3.13: Number of People Using Digital Therapeutics to Manage Diabetes (000's), Split by 8 Key Regions, 2021-2026
        • Table 3.14: Number of People Using Digital Therapeutics to Manage Diabetes (000's), Split by Payer, 2021-2026
      • ii. Total Diabetes Digital Therapeutics Revenue
        • Figure & Table 3.15: Total Diabetes Digital Therapeutics Revenue ($m), Split by Key Regions, 2021-2026
        • Table 3.16: Total Diabetes Digital Therapeutics Revenue ($m), Split by Payer, 2021-2026
    • 3.4.4 Physical Therapy
      • i. Number of People Who Receive Physical Therapy via Digital Therapeutics
        • Figure & Table 3.17: Number of People Who Receive Physical Therapy via Digital Therapeutics (000's), Split by 8 Key Regions, 2021-2026
        • Table 3.18: Number of People Who Receive Physical Therapy via Digital Therapeutics (000's), Split by Payer, 2021-2026
      • ii. Total Physical Therapy Digital Therapeutics Revenue
        • Figure & Table 3.19: Total Physical Therapy Digital Therapeutics Revenue ($m), Split by 8 Key Regions, 2021-2026
        • Table 3.20: Total Physical Therapy Digital Therapeutics Revenue ($m), Split by Payer, 2021-2026
    • 3.4.5 Smoking Cessation
      • i. Number of People Using Digital Therapeutics to Quit Smoking
        • Figure & Table 3.21: Number of People Using Digital Therapeutics to Quit Smoking (000's), Split by 8 Key Regions, 2021-2026
        • Table 3.22: Number of People Using Digital Therapeutics to Quit Smoking (000's), Split by Payer, 2021-2026
      • ii. Total Smoking Cessation Digital Therapeutics Revenue
        • Figure & Table 3.23: Total Smoking Cessation Digital Therapeutics Revenue ($m), Split by 8 Key Regions, 2021-2026
        • Table 3.24: Total Smoking Cessation Digital Therapeutics Revenue ($m), Split by Payer, 2021-2026
    • 3.4.6 Weight Management
      • i. Number of Obese or Overweight Adults Using Digital Therapeutics Manage Their Weight
        • Figure & Table 3.25: Number of Obese or Overweight Adults Using Digital Therapeutics to Manage Their Weight (000's), Split by 8 Key Regions, 2021-2026
        • Table 3.26: Number of Obese or Overweight Adults Using Digital Therapeutics Manage Their Weight (000's), Split by Payer, 2021-2026
      • ii. Total Weight Management Digital Therapeutics Revenue
        • Figure & Table 3.27: Total Weight Management Digital Therapeutics Revenue ($m), Split by 8 Key Regions, 2021-2026
        • Table 3.28: Total Weight Management Digital Therapeutics Revenue ($m), Split by Payer, 2021-2026

4. Market Overview: Digital Wellness

  • 4.1 Introduction
  • 4.2 Methodology & Assumptions
    • 4.2.1 Consumer Wellness
      • i. Number of People Using Digital Wellness Apps
      • ii. Number of Digital Wellness Apps in Use
      • iii. Number of Digital Wellness Apps That Are Monetised via Subscription Plans
      • iv. Total Consumer Digital Wellness Revenue
        • Figure 4.1: Consumer Digital Wellness Forecast Methodology
    • 4.2.2 Corporate Wellness
      • i. Number of Employees Enrolled in Corporate Wellness Programs
      • ii. Total Corporate Wellness Revenue
        • Figure 4.2: Corporate Digital Wellness Forecast Methodology
  • 4.3 Market Summary
    • 4.3.1 Number of People Using Digital Wellness Products
      • Figure & Table 4.3: Number of People Using Digital Wellness Products (m), Split by 8 Key Regions, 2021-2026
    • 4.3.2 Total Digital Wellness Revenue
      • Figure & Table 4.4: Total Digital Wellness Revenue ($m), Split by 8 Key Regions, 2021-2026
      • Table 4.5: Total Digital Wellness Revenue ($m), Split by Market Segment, 2021-2026
  • 4.4 Segment Market Forecasts
    • 4.4.1 Consumer Wellness
      • i. Number of People Using Digital Wellness Apps
        • Figure & Table 4.6: Number of People Using Digital Wellness Apps (m), Split by Key Regions, 2021-2026
      • ii. Number of Digital Wellness Apps in Use
        • Figure & Table 4.7: Number of Digital Wellness Apps in Use (m), Split by 8 Key Regions, 2021-2026
      • iii. Number of Digital Wellness Apps that Are Monetised via Subscription Plans
        • Figure & Table 4.8: Number of Digital Wellness Apps that Are Monetised via Subscription Plans (m), Split by 8 Key Regions, 2021-2026
      • iv. Total Consumer Digital Wellness Revenue
        • Figure & Table 4.9: Total Digital Wellness Revenue ($m), Split by 8 Key Regions, 2021-2026
    • 4.4.2 Corporate Wellness
      • i. Number of Employees Enrolled in Corporate Wellness Programmes
        • Figure & Table 4.10: Number of Employees Enrolled in Corporate Wellness Programmes (m), Split by 8 Key Regions, 2021-2026
      • ii. Total Corporate Digital Wellness Revenue
        • Figure & Table 4.11: Total Corporate Wellness Revenue ($m), Split by 8 Key Regions, 2021-2026